Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06298981 · ClinicalTrials.gov registry record
Pulse Rate and Breathing Rate Accuracy
A clinical trial of Pulse Rate and Breathing Rate, sponsored by Nuralogix Corporation.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT06298981 is a study of Pulse Rate and Breathing Rate that is actively recruiting participants, run by Nuralogix Corporation. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06298981, a study of Pulse Rate and Breathing Rate, is actively recruiting participants, sponsored by Nuralogix Corporation.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to conduct a Breathing Rate and Pulse Rate accuracy validation comparing the NuraLogix AMC-SDK to the Reference devices, an FDA cleared End Tidal Carbon Dioxide monitor (GE Datex-Ohmeda) and a standard ECG (GE Datex-Ohmeda) derived heart rate reference. This will be done by manually scoring the collected waveform for data analysis.
Conditions Studied
Interventions
- DEVICE noninvasive and investigational NuraLogix AMC-SDK
Study Locations (1)
Colorado
- Element Materials Technology - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-02-12 |
| Est. Completion | 2024-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06298981
The ClinicalTrials.gov registry entry for NCT06298981 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nuralogix Corporation, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulse Rate and Breathing Rate appearing as the primary indexed condition, and to 1 intervention - of which noninvasive and investigational NuraLogix AMC-SDK is the first listed.
NCT06298981 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT06298981 about?
NCT06298981 is a clinical study titled "Pulse Rate and Breathing Rate Accuracy". The purpose of this study is to conduct a Breathing Rate and Pulse Rate accuracy validation comparing the NuraLogix AMC-SDK to the Reference devices, an FDA cleared End Tidal Carbon Dioxide monitor (GE Datex-Ohmeda) and a standard ECG (GE Datex-Ohmeda) derived heart rate reference. This will be done...
What is the current status of trial NCT06298981?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2024-02-12. Estimated completion is 2024-06-30.
What conditions does trial NCT06298981 study?
This clinical trial studies the following conditions: Pulse Rate and Breathing Rate.
What interventions are being tested in trial NCT06298981?
The interventions under investigation include: noninvasive and investigational NuraLogix AMC-SDK (DEVICE).
Who is sponsoring clinical trial NCT06298981?
This trial is sponsored by Nuralogix Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06298981 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.